| SEC Form 4 |
|------------|
|------------|

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 |
|------------------------|-----------|
| Estimated average bure | den |
| hours per response: | 0.5 |

By

Family Trust 4 By

Spouse

T

Ι

| STATEMENT | OF (| CHANGE | s in | BENEF | OWNE | RSHIP |
|-----------|------|--------|------|-------|------|-------|
| | | | | | | |

| Check this box it Section 16. Form obligations may Instruction 1(b). | | to STA ⁻ | Filed pursua | F CHANGES ant to Section 16(a) action 30(h) of the In | of the S | ecuriti | es Exchange A | Act of 193 | _ | E | OMB Number: Estimated average bu nours per response: | 3235-0287 rden 0.5 | |
|---|-------------------|--|---|---|-------------------------|--|---------------|------------------|---|---|--|--------------------------|--|
| 1. Name and Addre | ss of Reporting P | erson* | | er Name and Ticke | | | | 1 | | | orting Person(s) to | ssuer | |
| Struthers Ric | hard Scott | | <u>Crin</u> | Crinetics Pharmaceuticals, Inc. [CRNX] | | | | | | | (Check all applicable) X Director 10% O | | |
| (Last) | (First) | 05/08 | e of Earliest Transac /2024 | ction (M | onth/E |)ay/Year) | | x | Officer (give t below) Pres | title Othe belo sident & CEO | er (specify w) | | |
| C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD | | | | mendment, Date of | Original | Filed | (Month/Day/Ye | 6. Indi Line) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | |
| (Street) SAN DIEGO | СА | | | | | | | X | | <pre>/ One Reporting Pei / More than One Re</pre> | | | |
| (City) | (State) | (Zip) | | e 10b5-1(c) T | | | | | to a contract | instruction or wri | itten olan that is inten | led to satisfy | |
| | | | | e affirmative defense | | | | | | | | ieu to satisty | |
| | | Table I - No | n-Derivative S | Securities Acq | uired, | Dis | posed of, o | or Ben | eficially | Owned | | | |
| 1. Title of Security | (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 | | | 5. Amount of Securities Beneficially Owned Followi | 6. Ownership Form: Direct (D) or Indirect ing (I) (Instr. 4) | Ownership | | |
| | | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | (Instr. 4) | | |
| Common Stock | | | 05/08/2024 | | М | | 107,448 | A | \$9.28 | 364,933 | D | | |
| Common Stock | | | 05/08/2024 | | S ⁽¹⁾ | | 107,448 | D | \$49.4(2) | 257,485 | D | | |
| Common Stock | | | | | | | | | | 570,805 | I | By Family Trust 1 | |
| Common Stock | | | | | | | | | | | | Du | |
| | | | | | | | | | | 110,000 | Ι | By Family Trust 2 | |

Common Stock

Common Stock

| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | |
|------------|---|----------------|-----------|----------|--------------|------------|------|
| Table II - | Derivative Se | curities Acqui | ired, Dis | sposed o | of, or Benei | ficially O | wned |
| | la a nuta aa | lls. warrants. | antiana | | سيممم ماطنا | ition) | |
| | (e.u., puls, ca | iis. warrants. | opuons | . conver | lible secur | lues | |

| | (3 , p,, -p, -p, | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|------------|---------|--|--------------------|---|-------------------------------------|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | Derivative | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| Stock Option (Right to Buy) | \$9.28 | 05/08/2024 | | М | | | 107,448 | (3) | 05/24/2028 | Common Stock | 107,448 | \$0 | 16,342 | D | |

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan entered into in March 2023.

2. The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of \$49.40 per share. The range of sales prices on the transaction date was \$48.95 to \$50.15 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

3. 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date

> Marc Wilson, as attorney-in-05/10/2024 fact

** Signature of Reporting Person

Date

110,000

1,000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.